A new TB vaccine candidate has entered Phase I clinical trials in South Africa to assess its safety and immunogenicity in latently infected adults. The vaccine, SSI H56-IC31, has shown efficacy in pre-clinical studies and holds promise for preventing active TB disease in a vast population.
The Aeras Global TB Vaccine Foundation has received an additional €11.7 million grant from the Netherlands Ministry of Foreign Affairs to develop new vaccines against tuberculosis.
The Aeras Global TB Vaccine Foundation has received a $362,102 grant from the US FDA to develop new biological and immunological biomarkers for TB vaccine development. The project aims to evaluate four mycobacterial growth inhibition assays and identify T-cell immune responses associated with protective vaccines.
A new TB vaccine candidate called AERAS-422 is undergoing clinical trials to evaluate its safety and immunogenicity. The vaccine aims to interrupt TB at all stages of infection, including initial infection, latency, and reactivation.
The Phase II study will establish the optimal dosing regimen and then be tested in Kenya, Mozambique, South Africa, and Uganda. The TB vaccine candidate has been shown to have an acceptable safety profile in early-stage clinical trials.
Researchers will test the AERAS-402/Crucell Ad35 vaccine candidate in people living with HIV, aiming to induce critical CD8 immune cells. The study is crucial for developing an effective TB vaccine, especially for those with HIV, who are 20 times more likely to develop TB.
Aeras and UCLA announce a license deal for rBCG30, a live recombinant vaccine technology developed at UCLA's David Geffen School of Medicine. The vaccine has shown promising results in initial clinical studies and holds potential to reduce TB disease burden globally.
The collaboration aims to improve the BCG vaccine, which offers protection against serious forms of TB in childhood but loses efficacy over time. A new vaccine is crucial to combating the disease that kills over two million people globally per year.
A new TB vaccine, rBCG30, is being tested in a human clinical trial to assess its safety and immune response. The vaccine, developed by Dr. Marcus Horwitz and his team at UCLA, has shown promise in preclinical trials and could potentially reduce the TB disease burden worldwide.
The Sequella Global Tuberculosis Foundation has awarded $500,000 in grants to nine researchers working on innovative tuberculosis vaccines. The grants will fund projects using novel adjuvants, delivery mechanisms, and immunological approaches.
The Sequella Global Tuberculosis Foundation invites researchers worldwide to apply for $50,000 grants to develop effective vaccines for human tuberculosis. The program aims to spur innovation and encourage new approaches to vaccine development.